

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
9 August 2007 (09.08.2007)

PCT

(10) International Publication Number
WO 2007/088034 A3

(51) International Patent Classification:

A61K 31/436 (2006.01) A61P 35/00 (2006.01)
A61K 31/365 (2006.01) A61P 25/00 (2006.01)
A61K 31/351 (2006.01)

STUMM, Michael [CH/CH]; Bäumlihofstrasse 377,
CH-4125 Riehen (CH).

(74) Agent: LEON, Susanna; Novartis AG, Corporate Intel-
lectual Property, CH-4002 Basel (CH).

(21) International Application Number:

PCT/EP2007/000818

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS,
LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date: 31 January 2007 (31.01.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0602123.2 2 February 2006 (02.02.2006) GB
0603568.7 22 February 2006 (22.02.2006) GB
0604593.4 7 March 2006 (07.03.2006) GB
0605760.8 22 March 2006 (22.03.2006) GB
0609698.6 16 May 2006 (16.05.2006) GB

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except AT, US): NO-
VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel
(CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(72) Inventors; and

(75) Inventors/Applicants (for US only): BERG, William
[US/US]; 10 Hallmark Drive, New City, NY 10956 (US).
BENEDETTO, John [US/US]; 35 Hancock Drive, Mor-
ristown, NJ 07960 (US). ELMROTH, Ingrid [CH/CH];
Mohrhaldenstrasse 155, CH-4125 Riehen (CH). LANE,
Heidi [CH/CH]; Jakobsweg 22, CH-4105 Biel-Benken
(CH). LEBWOHL, David [US/US]; 55 Pomeroy Road,
Madison, NJ 07940 (US). SELLERS, William [US/US];
50 Cleveland Road, Chestnut Hill, MA 02467 (US).

Published:

— with international search report

(88) Date of publication of the international search report:

1 November 2007

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: TUBEROUS SCLEROSIS TREATMENT

(57) Abstract: Rapamycin derivatives for use in the treatment of neurocutaneous disorders.



WO 2007/088034 A3

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2007/000818

A. CLASSIFICATION OF SUBJECT MATTER
 INV. A61K31/436 A61K31/365 A61K31/351 A61P35/00 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
 EPO-Internal, WPI Data, CHEM ABS Data, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,Y	WO 2005/052187 A (UNIV MICHIGAN [US]; GUAN KUN-LIANG [US]) 9 June 2005 (2005-06-09) claims 6,7 page 43, line 1 - page 45, line 29 page 45, lines 4-14	1-15
X,Y	WO 02/11742 A (ONCOLYTICS BIOTECH INC [CA]; COFFEY MATTHEW C [CA]; THOMPSON BRADLEY G) 14 February 2002 (2002-02-14) page 18, line 25 claims 1,12,37-39 page 1, lines 5-15	1-15
Y	WO 2004/073614 A (COMBINATORX INC [US]; JOST-PRICE EDWARD ROYDON [US]; BRASHER BRADLEY B) 2 September 2004 (2004-09-02) page 16, line 23 - page 17, line 4 page 19, line 12, paragraph 15	1-15
	----- -/--	

Further documents are listed in the continuation of Box C. See patent family annex.

- * Special categories of cited documents :
- *A* document defining the general state of the art which is not considered to be of particular relevance
 - *E* earlier document but published on or after the international filing date
 - *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 - *O* document referring to an oral disclosure, use, exhibition or other means
 - *P* document published prior to the international filing date but later than the priority date claimed
 - *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 - *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 - *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 - *8* document member of the same patent family

Date of the actual completion of the international search 24 April 2007	Date of mailing of the international search report 14/06/2007
--	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Tullberg, Erik
---	--

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2007/000818

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GEMMILL R M ET AL: "Synergistic Growth by Iressa and Rapamycin is modulated by VHL mutation in renal cell carcinoma" BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 92, June 2005 (2005-06), pages 2266-2277, XP003001047 ISSN: 0007-0920 abstract -----	1-15
A	DASGUPTA BIPLAB ET AL: "Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors" CANCER RESEARCH, vol. 65, no. 7, April 2005 (2005-04), pages 2755-2760, XP002430708 ISSN: 0008-5472 abstract -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/EP2007/000818

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 2005052187	A	09-06-2005	CN	1910291 A	07-02-2007
				EP 1692305 A1	23-08-2006
WO 0211742	A	14-02-2002	AR	029839 A1	16-07-2003
				AU 7621801 A	18-02-2002
				BR 0113128 A	22-07-2003
				CA 2415750 A1	14-02-2002
				EP 1309334 A2	14-05-2003
				JP 2004505924 T	26-02-2004
				MX PA03000859 A	05-04-2004
				NZ 523509 A	26-11-2004
				ZA 200300411 A	26-01-2004
WO 2004073614	A	02-09-2004	AU	2004212919 A1	02-09-2004
				CA 2514061 A1	02-09-2004
				EP 1599212 A2	30-11-2005
				HR 20050804 A2	28-02-2006
				IS 8023 A	13-09-2005
				JP 2006517969 T	03-08-2006
				KR 20050110634 A	23-11-2005
				MX PA05008649 A	23-11-2005
US 2006160837	A1	20-07-2006	NONE		